Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-06-03 18:05:24 Source:businessViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Previous:Real Madrid celebrates another Champions League title with its fans on streets of Spanish capital
Next:Three Maryland family members fatally shot, another wounded, suspect takes own life, police say
You may also like
- Welcome to Frankenmuth, the bizarre 'German' city that could swing the US election
- Drake and Kendrick Lamar's feud, explained
- Jurors should have considered stand
- Woman, 31, was left 'burning from the inside out' in 17
- Maldives will ban Israelis from entering the country over the war in Gaza
- Indiana professors sue after GOP lawmakers pass law regulating faculty tenure
- Preakness status of Kentucky Derby winner Mystik Dan remains unclear
- Victim of road
- Paris Olympics: What to know and who to watch during the canoe/kayak competition